id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-288009-8i3gsq9p	Javor, S.	Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?	2020-04-25		.txt	text/plain	668	50	46	Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy Bosentan is a dual endothelin-receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH) in New York Heart Association functional classification (NYHA) II-IV and in scleroderma patients [10] . Guo et al [13] described a case of 57-year-old man with influenza A (H7N9) virus infection initially treated with empirical antibacterial therapy and oseltamivir with progression to acute respiratory distress syndrome and mechanical ventilation. Ritonavir and lopinavir, given together to sup-press HIV-replication, have been associated with bosentan to treat PAH in HIV-infected patients without dosage adjustment of protease inhibitors with good tolerability [14] . In conclusion, we think bosentan could be considered, in association with other approved drugs, in the treatment of SARS-CoV-2 to improve hemodynamics, potentiate antiviral effects and to prevent lung fibrosis. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells	./cache/cord-288009-8i3gsq9p.txt	./txt/cord-288009-8i3gsq9p.txt